The latest survey from the National Venture Capital Association shows that biotechnology is still on a roll [1]with investors. The association tracked 99 biotech deals in the third quarter which were worth $1.1 billion. Frazier Healthcare Ventures is so pumped about developers it's reserved half of its latest $600 million fund for biotech deals. An ongoing obstacle: A reluctance among VCs to back early-stage ventures. Most worrisome trend: The prospect that a new group of politicos in charge of healthcare legislation [2] in Washington DC will chill the life sciences field with talk of reform.

- read the report [3] from BioWorld on venture capital trends

Related Articles:
Venture capitalists bet big on nanotechnology. Report [4]
Bill could improve funding for small biotechs. Report [5]
Biotech sees big money from corporate players. Report [6]
The Top 5 VC deals of the first half of 2007. Report [7]